You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Advanced Prediction of Emerging Respiratory Decline with the Linshom Continuous Predictive Respiratory Sensor (CPRS)

    SBC: LINSHOM MEDICAL INC            Topic: NHLBI

    Abstract: This Fast-track SBIR application will fund and enable a new approach to respiratory monitoring, continuous predictive respiratory monitoring (CPRM), that stands to reduce morbidity and mortality due to respiratory compromise, while reducing health care system costs. Current devices and systems (human and machine) for respiratory monitoring are responsive by sounding a warning alarm when ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis

    SBC: PROTHERA BIOLOGICS, INC.            Topic: NICHD

    Necrotizing enterocolitis (NEC) is a devastating acute inflammatory condition of the gastrointestinal tract resulting in intestinal necrosis, systemic sepsis and multi-system organ failure found mostly in infants born prematurely. Despite modern medical advances in the past decade, the etiology remains elusive and morbidity and mortality are still unacceptably high. It has been concluded that the ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Selective CYP26 inhibitors for the oral treatment of recalcitrant nodular acne.

    SBC: DERMAXON LLC            Topic: NIAMS

    Project Summary / Abstract DermaXon's project goal is to develop efficacious, substrate-based, selective inhibitors of CYP26s, the enzymes responsible for the metabolism of all-trans retinoic acid (atRA) in the epidermis, as an oral treatment for severe recalcitrant acne. This approach will provide an improved acne therapeutic without the adverse effects associated with currently marketed retinoid ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. PET Imaging to Evaluate a Novel Chemokine Antagonist to Protect Synapses in ADRD

    SBC: CREATIVE BIO-PEPTIDES INC            Topic: NIA

    7. Project Summary ADRD dementias account for up to 25% of all dementias in patients older than 65 years and there is strong evidence of co-morbid pathologies caused by (amyloid β (Aβ), tau and α-synuclein (αSyn). The degree of AD- related pathology in Lewy Body Dementias (LBD) is moderate or severe in 50% of PDD and more than 70% of DLB patients have concomitant AD-related pathology so that t ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Booth™ by Opio™: Developing technology to expand the reach of opioid treatment programs into rural and underserved areas.

    SBC: Opio Connect, Inc.            Topic: NIDA

    The goal of this project is to develop a treatment booth with technology that allows opioid treatment programs to remotely dispense, either methadone or buprenorphine, under medical observation through telemedicine to a patient in a treatment booth. We believe that robotic automation is the ideal application to perform the same mechanical functions of the nurse at the dosing window. Specifically, ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. PET Imaging of Damaging Neuroinflammation in Alzheimer's Disease

    SBC: EINSENCA INC.            Topic: NIA

    Alzheimer's disease (AD) is a devastating and progressive disease without a cure. Neuroinflammation is now recognized as a key early event in the development of AD. Aberrant neuroinflammatory response activates immune cells that can increase oxidative stress, and oxidative stress can directly damage neurons and axons, cause demyelination, and break down the blood-brain barrier (BBB). Thus, damagin ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, INC.            Topic: 105

    Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Pharmacogenomics Workflow: Identifying Biomarkers and Treatment Options

    SBC: Golden Helix, Inc.            Topic: 172

    Abstract Pharmacogenomics, the study of how an individual's genetic makeup affects their response to drugs, has undergone rapid advancements. This has occurred alongside a decrease in the cost of genotyping technology, making implementation of pharmacogenomics into clinical practice increasingly feasible. Personalized medicine leveraging pharmacogenomics is gaining momentum to optimize drug choice ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Mindfulness Based Stress Reduction App for African American Caregivers

    SBC: COG ANALYTICS, LLC            Topic: R

    AbstractThere are approximately 43.5 million informal (unpaid) caregivers in the U.S., of which 5.6 million are African American.1 Almost one third of people living with HIV/AIDS (PLWHA) report receiving care from informal caregivers, typically friends and family.2 Informal caregivers often provide a variety of support to PLWHA, including emotional and instrumental, financial assistance, and healt ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Treatment of status epilepticus and refractory status epilepticus with intravenous topiramate.

    SBC: PREVEP, LLC            Topic: NINDS

    Abstract Status epilepticus (SE) is a common neurologic emergency that fails to respond to first- and second-line anti-seizure medications (ASMs) in about one third of instances, thus progressing to refractory SE (RSE). Patients with RSE are at grave risk for neurological morbidity and mortality. The recently completed NIH-funded Established SE Treatment Trial (ESETT) highlights the need for impro ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government